Skip to main content
. 2021 May 11;13(10):2290. doi: 10.3390/cancers13102290

Figure 2.

Figure 2

Longitudinal evaluation of the circulating tumor cells (CTCs) detected in the patient samples. (a) Distribution of the total number of CTCs from the patients at the baseline (n = 44), week 4 (n = 31), week 8 (n = 16), week 12 (n = 13), and week 24 (n = 11). (b) Distribution of the number of programmed death-ligand 1 (PD-L1)-positive CTCs from the patients at each evaluation point. * p < 0.05. (c) Distribution of the PD-L1 positivity rates in the patients at each evaluation point. * p < 0.05. Orange dots indicate the patients who were diagnosed PD during the next blood draw. Transition of the number of CTCs (d), number of PD-L1-positive CTCs (e), and PD-L1 positivity rates in the detected CTCs (f) from the patients receiving nivolumab treatment for more than 24 weeks (n = 11). The patterns of the CTC status change were classified into three types. Green indicates the first type (N4, N20, N42, and N43); pink indicates the second type (N16, N23, N26, and N30); and gray indicates other type (N21, N35, and N37).